| Title |
Green tea halts progression of cardiac transthyretin amyloidosis: an observational report
|
|---|---|
| Published in |
Clinical Research in Cardiology, May 2012
|
| DOI | 10.1007/s00392-012-0463-z |
| Pubmed ID | |
| Authors |
Arnt V. Kristen, Stephanie Lehrke, Sebastian Buss, Derliz Mereles, Henning Steen, Philipp Ehlermann, Stefan Hardt, Evangelos Giannitsis, Rupert Schreiner, Uwe Haberkorn, Philipp A. Schnabel, Reinhold P. Linke, Christoph Röcken, Erich E. Wanker, Thomas J. Dengler, Klaus Altland, Hugo A. Katus |
| Abstract |
Treatment options in patients with amyloidotic transthyretin (ATTR) cardiomyopathy are limited. Epigallocatechin-3-gallate (EGCG), the most abundant catechin in green tea (GT), inhibits fibril formation from several amyloidogenic proteins in vitro. Thus, it might also halt progression of TTR amyloidosis. This is a single-center observational report on the effects of GT consumption in patients with ATTR cardiomopathy. |
X Demographics
The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 43% |
| Argentina | 1 | 14% |
| Unknown | 3 | 43% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 135 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 2 | 1% |
| United States | 1 | <1% |
| Portugal | 1 | <1% |
| Italy | 1 | <1% |
| Unknown | 130 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 24 | 18% |
| Other | 15 | 11% |
| Student > Bachelor | 14 | 10% |
| Student > Doctoral Student | 12 | 9% |
| Student > Ph. D. Student | 11 | 8% |
| Other | 31 | 23% |
| Unknown | 28 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 46 | 34% |
| Agricultural and Biological Sciences | 15 | 11% |
| Biochemistry, Genetics and Molecular Biology | 8 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 5% |
| Chemistry | 6 | 4% |
| Other | 16 | 12% |
| Unknown | 37 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 June 2019.
All research outputs
#5,965,990
of 22,696,971 outputs
Outputs from Clinical Research in Cardiology
#212
of 806 outputs
Outputs of similar age
#41,389
of 163,728 outputs
Outputs of similar age from Clinical Research in Cardiology
#2
of 7 outputs
Altmetric has tracked 22,696,971 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 806 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 26.5. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 163,728 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.